In recent weeks, two major medical organizations have issued independent warnings about toxic chemicals in products all around us. Unregulated substances, they say, are sometimes linked to breast and prostate cancer, genital deformities, obesity, diabetes and infertility.
Tag: prostate cancer
Can Cycling Crimp Sex for Men?
With the quiet explosion in popularity of recreational bicycling in the United States, it’s natural that men would wonder about the potential health effects of spending serious time on a bike. Men, research shows, account for almost all the growth in the pastime in the last three decades. A recent study both silences some of the most prevalent fears, which center on sexual dysfunction and infertility, and raises the specter of another. It suggests that prolonged cycling may be linked to higher risks of prostate cancer in men over age 50.
Cycling Doesn’t Cause Male Infertility: Study
Cycling doesn’t lead to male infertility and erectile dysfunction, but it may raise prostate cancer risk in cyclists over 50, a new study finds.
New Approach May Boost Survival From Advanced Prostate Cancer
Adding the chemotherapy drug docetaxel to standard hormone-depleting therapy may extend the lives of men with advanced prostate cancer, a new study finds.
Gene Affects Sperm’s Ability
A gene known to affect hormone action in breast and prostate cancer cells has now been proven to have an impact on male fertility, according to research by a team including cancer specialists from The University of Western Australia.
On-and-Off Approach to Prostate Cancer Treatment May Compromise Survival
Taking a break from hormone-blocking prostate cancer treatments once the cancer seems to be stabilized is not equivalent to continuing therapy, a new large-scale international study finds.
Taking Breaks From Prostate Cancer Hormone Therapy Seems Safe: Study
WEDNESDAY, Sept. 5 (HealthDay News) — Stop-and-start hormone-deprivation therapy for localized prostate cancer doesn’t shorten overall survival compared to continuous treatments, andyields fewer side effects such as impotence and hot flashes, a large new study suggests.
A team of Canadian, British and American researchers found that intermittent hormone treatments — which suppress circulating male hormones such as testosterone that “feed” prostate tumors — don’t increase the risk of disease progression. Intermittent treatment also doesn’t increase the chances that patients whose prostate-specific antigen (PSA) levels are slowly rising will eventually die from prostate cancer. Read full article.